Document is current
Any future updates will be listed below
-
Authors
Tambe, Mahesh https://orcid.org/0000-0002-9345-4022
Unterberger, Sarah
Kriegbaum, Mette C.
Vänttinen, Ida
Olgac, Ezgi June
Vähä-Koskela, Markus
Kontro, Mika
Wennerberg, Krister https://orcid.org/0000-0002-1352-4220
Heckman, Caroline A. https://orcid.org/0000-0002-4324-8706
-
Funding
Funding for this research was provided by:
Syöpäsäätiö
Sigrid Juséliuksen Säätiö
Academy of Finland (357686, 334781, 352265, 320185)
Novo Nordisk Fonden (NNF21OC0072481)
- License Information
-
More Information
Article History
Received: 17 November 2023
Revised: 2 October 2024
Accepted: 7 October 2024
First Online: 16 October 2024
Competing interests
: MKo reports personal fees from Astellas Pharma, AbbVie, Bristol-Myers Squibb, Faron, Jazz, Pharmaceuticals, Novartis, and Pfizer and research funding from AbbVie outside the submitted work. CAH has received honoraria from Amgen, personal fees from Autolus, and research funding from Celgene/BMS, Kronos Bio, Novartis, Oncopeptides, Orion Pharma, WntReseach, Zentalis Pharmaceuticals, and the IMI2 projects HARMONY and HARMONY PLUS unrelated to this study. MCK is currently an employee of Ascendis Pharma.
: The samples were collected after obtaining a signed informed consent and using protocols in accordance with the Declaration of Helsinki. The study has been approved by a Helsinki University Hospital Ethical Committee (permits 303/13/03/01/2011 and HUS/3235/2019).
